fenofibrate has been researched along with Coronary Disease in 70 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the efficacy and safety profile of fluvastatin + fenofibrate combination therapy and those of fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus (DM), and coronary heart disease (CHD) (ie, high risk for cardiovascular disease [CVD])." | 9.11 | Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. ( Bertone, G; Ciccarelli, L; Cicero, AE; Derosa, G; Piccinni, MN; Roggeri, DE, 2004) |
| "The authors review current literature on the use of fenofibrate and related derivatives in HIV-infected people with dyslipidemia using antiretroviral therapy." | 8.86 | Fenofibrate in the treatment of dyslipidemia associated with HIV infection. ( Fichtenbaum, CJ; Samineni, D, 2010) |
| "To compare the effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation with the standard 160-mg tablet in patients with dyslipidemia and coronary heart disease." | 7.74 | Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. ( Hilleman, D; Maciejewski, S, 2008) |
| "To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia." | 7.72 | The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. ( Balogh, Z; Boda, J; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Szilvássy, Z, 2003) |
| "Eighty patients with coronary heart disease with a baseline low-density lipoprotein cholesterol (LDL) level above 130 mg/dl or a triglyceride level of 200 mg/dl or higher who had been receiving gemfibrozil 600 mg twice/day." | 7.71 | Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002) |
| "The effect of fenofibrate (a clofibrate derivative) on fibrinogen concentration, blood viscosity and myocardial microcirculation was examined in 35 patients with coronary heart disease (n = 27) or hypertension (n = 8)." | 7.67 | [Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?]. ( Blanke, H; Egbring, R; Höffken, H; Joseph, K; Leschke, M; Schmidtsdorff, A; Strauer, BE, 1989) |
| " The safety of the treatment was assessed by recording adverse events and measuring clinical laboratory parameters." | 6.71 | [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Jakóbisiak-Ostasz, B; Kłosiewicz-Latoszek, L; Respondek, W; Stolarska, I, 2003) |
| "The aim of this study was to compare the efficacy and safety profile of fluvastatin + fenofibrate combination therapy and those of fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus (DM), and coronary heart disease (CHD) (ie, high risk for cardiovascular disease [CVD])." | 5.11 | Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. ( Bertone, G; Ciccarelli, L; Cicero, AE; Derosa, G; Piccinni, MN; Roggeri, DE, 2004) |
| "The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus." | 5.11 | Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. ( Barter, P; Best, J; Forder, P; Keech, A; Scott, R; Simes, J; Taskinen, MR, 2005) |
| "The long-term efficacy and safety of fluvastatin monotherapy was compared with that of the combination of fluvastatin and fenofibrate in 104 patients with coronary heart disease and combined hyperlipidemia in an open, randomised, parallel group, clinical study of 78 weeks duration." | 5.09 | [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate]. ( Balazovjech, I; Hulínský, V; Lánská, V; Widimský, J, 1999) |
| "The authors review current literature on the use of fenofibrate and related derivatives in HIV-infected people with dyslipidemia using antiretroviral therapy." | 4.86 | Fenofibrate in the treatment of dyslipidemia associated with HIV infection. ( Fichtenbaum, CJ; Samineni, D, 2010) |
| " High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate." | 4.84 | Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE. ( Robinson, JG, 2007) |
| "Patients with type 2 diabetes mellitus die of cardiovascular disease (CVD) at rates 2-4 times higher than patients without diabetes but with similar demographic characteristics." | 3.82 | Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. ( Buse, JB; Byington, RP; Cushman, WC; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Margolis, KL; Probstfield, JL; Simons-Morton, DG, 2007) |
| "To compare the effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation with the standard 160-mg tablet in patients with dyslipidemia and coronary heart disease." | 3.74 | Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. ( Hilleman, D; Maciejewski, S, 2008) |
| "To evaluate the effect of micronised fenofibrate on serum paraoxonase (PON) and lipoprotein levels in coronary heart disease patients with type IIb hyperlipidemia." | 3.72 | The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. ( Balogh, Z; Boda, J; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Szilvássy, Z, 2003) |
| "Eighty patients with coronary heart disease with a baseline low-density lipoprotein cholesterol (LDL) level above 130 mg/dl or a triglyceride level of 200 mg/dl or higher who had been receiving gemfibrozil 600 mg twice/day." | 3.71 | Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ( Backes, JM; Destache, C; Hilleman, DE; Lenz, TL; Packard, KA; Wurdeman, RL, 2002) |
| "The effect of fenofibrate (a clofibrate derivative) on fibrinogen concentration, blood viscosity and myocardial microcirculation was examined in 35 patients with coronary heart disease (n = 27) or hypertension (n = 8)." | 3.67 | [Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?]. ( Blanke, H; Egbring, R; Höffken, H; Joseph, K; Leschke, M; Schmidtsdorff, A; Strauer, BE, 1989) |
| " Combination therapy was generally well tolerated with incidences of clinical and laboratory adverse experiences similar between the 2 groups." | 2.75 | Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. ( Bryniarski, L; Ducobu, J; Farnier, M, 2010) |
| " The safety of the treatment was assessed by recording adverse events and measuring clinical laboratory parameters." | 2.71 | [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease]. ( Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Jakóbisiak-Ostasz, B; Kłosiewicz-Latoszek, L; Respondek, W; Stolarska, I, 2003) |
| "Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy." | 2.71 | Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| " Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates." | 2.43 | Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. ( Davidson, MH, 2006) |
| "Fenofibrate has favorable pleiotropic effects on several features of the metabolic syndrome, which are likely to explain the clinical benefits of fibrate therapy, beyond an impact on HDL-C levels." | 2.41 | Increasing high-density lipoprotein cholesterol: an update on fenofibrate. ( Després, JP, 2001) |
| "Fenofibrate is a broad spectrum lipid-lowering agent able to produce substantial reductions in plasma triglyceride and low density lipoprotein (LDL) and an increase in high density lipoprotein (HDL)." | 2.40 | Overview of fenofibrate. ( Packard, CJ, 1998) |
| "Dyslipidemia is believed to be a major source of this increased risk." | 2.40 | Diabetes, hyperlipidemia, and coronary artery disease. ( Haffner, SM, 1999) |
| "Fibric acid derivatives may interact with other drugs and the interactions can be of clinical relevance." | 2.39 | Drug interactions with fibric acids. ( Dujovne, CA; Lozada, A, 1994) |
| " Micronized fenofibrate, a new formulation chemically identical to the parent compound, has improved pharmacokinetic parameters which increase absorption, provide more stable plasma levels, and thus dosage can be decreased." | 2.39 | The fibrates in clinical practice: focus on micronised fenofibrate. ( Shepherd, J, 1994) |
| "Fenofibrate is a fibric acid derivative that has been available in much of the world for over 10 years." | 2.38 | Treatment of hypercholesterolaemia with fenofibrate: a review. ( Brown, WV, 1989) |
| "The prevention and treatment of coronary heart disease is a major challenge in the overall management of the patient with type 2 diabetes." | 1.31 | Status report of lipid-lowering trials in diabetes. ( Armitage, J; Betteridge, DJ; Colhoun, H, 2000) |
| "The purpose of this study was to investigate the effect of low high-density-lipoprotein (HDL) combined with hypertriglyceridemia in coronary artery disease (CAD) patients on prostaglandin I2 (PGI2) biological activity in relation to lipid regulating treatment." | 1.30 | Effect of low HDL combined with hypertriglyceridemia in coronary artery disease patients on PGI2 biological activity in relation to lipid regulating treatment. ( Dai, G; Feng, Z; Li, J; Wang, C; Wei, W; Yang, Y; Zhou, B, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.29) | 18.7374 |
| 1990's | 17 (24.29) | 18.2507 |
| 2000's | 37 (52.86) | 29.6817 |
| 2010's | 12 (17.14) | 24.3611 |
| 2020's | 1 (1.43) | 2.80 |
| Authors | Studies |
|---|---|
| Sheng, CS | 1 |
| Miao, Y | 1 |
| Ding, L | 1 |
| Cheng, Y | 1 |
| Wang, D | 2 |
| Yang, Y | 2 |
| Tian, J | 1 |
| Vazzana, N | 1 |
| Ganci, A | 1 |
| Cefalù, AB | 1 |
| Lattanzio, S | 1 |
| Noto, D | 1 |
| Santoro, N | 1 |
| Saggini, R | 1 |
| Puccetti, L | 1 |
| Averna, M | 1 |
| Davì, G | 1 |
| Al-Waili, K | 1 |
| Al-Zakwani, I | 1 |
| Al-Dughaishi, T | 1 |
| Baneerje, Y | 1 |
| Al-Sabti, H | 1 |
| Al-Hashmi, K | 1 |
| Farhan, H | 1 |
| Habsi, KA | 1 |
| Al-Hinai, AT | 1 |
| Al-Rasadi, K | 1 |
| Kitajima, S | 1 |
| Furuichi, K | 1 |
| Wada, T | 1 |
| Kumar, S | 1 |
| Rai, H | 1 |
| Kapoor, A | 1 |
| Tewari, S | 1 |
| Sinha, N | 1 |
| Page, MM | 1 |
| Ekinci, EI | 1 |
| Jones, RM | 1 |
| Angus, PW | 1 |
| Gow, PJ | 1 |
| O'Brien, RC | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Samineni, D | 1 |
| Fichtenbaum, CJ | 1 |
| Ruiz, J | 1 |
| Egli, M | 1 |
| Gianinazzi, F | 1 |
| Izzo, F | 1 |
| Voeffray Favre, AC | 1 |
| Rossi, I | 1 |
| Bodenman, P | 1 |
| Farnier, M | 1 |
| Ducobu, J | 1 |
| Bryniarski, L | 1 |
| Sacks, FM | 1 |
| Carey, VJ | 1 |
| Fruchart, JC | 3 |
| Dolgin, E | 1 |
| Chang, CN | 1 |
| How, CH | 1 |
| Tavintharan, S | 1 |
| Leinonen, ES | 1 |
| Salonen, JT | 1 |
| Salonen, RM | 1 |
| Koistinen, RA | 1 |
| Leinonen, PJ | 1 |
| Sarna, SS | 1 |
| Taskinen, MR | 6 |
| Márk, L | 1 |
| Császár, A | 1 |
| Ceska, R | 1 |
| Stulc, T | 1 |
| Zima, T | 1 |
| Malbohan, I | 1 |
| Fialova, L | 1 |
| Packard, KA | 1 |
| Backes, JM | 1 |
| Lenz, TL | 1 |
| Wurdeman, RL | 1 |
| Destache, C | 1 |
| Hilleman, DE | 1 |
| Nagai, Y | 1 |
| Yamashita, S | 1 |
| Tuomilehto, J | 1 |
| Lemieux, I | 2 |
| Salomon, H | 2 |
| Després, JP | 3 |
| Kłosiewicz-Latoszek, L | 1 |
| Respondek, W | 1 |
| Białobrzeska-Paluszkiewicz, J | 1 |
| Grzybowska, B | 1 |
| Jakóbisiak-Ostasz, B | 1 |
| Stolarska, I | 1 |
| Paragh, G | 1 |
| Seres, I | 1 |
| Harangi, M | 1 |
| Balogh, Z | 1 |
| Illyés, L | 1 |
| Boda, J | 1 |
| Szilvássy, Z | 1 |
| Kovács, P | 1 |
| Hepburn, AL | 1 |
| Feher, MD | 2 |
| Dobordzhginidze, LM | 1 |
| Derosa, G | 1 |
| Cicero, AE | 1 |
| Bertone, G | 1 |
| Piccinni, MN | 1 |
| Ciccarelli, L | 1 |
| Roggeri, DE | 1 |
| Hay, JW | 1 |
| Sterling, KL | 1 |
| de Lorgeril, M | 3 |
| Salen, P | 3 |
| Guiraud, A | 1 |
| Zeghichi, S | 1 |
| Boucher, F | 1 |
| de Leiris, J | 1 |
| Scott, R | 3 |
| Best, J | 3 |
| Forder, P | 2 |
| Simes, J | 2 |
| Barter, P | 3 |
| Keech, A | 3 |
| Davidson, MH | 2 |
| Noda, K | 1 |
| Zhang, B | 1 |
| Uehara, Y | 1 |
| Miura, S | 1 |
| Matsunaga, A | 1 |
| Saku, K | 1 |
| Simes, RJ | 1 |
| Pillai, A | 1 |
| Davis, T | 1 |
| Glasziou, P | 1 |
| Drury, P | 1 |
| Kesäniemi, YA | 1 |
| Sullivan, D | 1 |
| Hunt, D | 1 |
| Colman, P | 1 |
| d'Emden, M | 1 |
| Whiting, M | 1 |
| Ehnholm, C | 1 |
| Laakso, M | 1 |
| Robinson, JG | 1 |
| Sharma, R | 1 |
| Mahajan, M | 1 |
| Singh, B | 1 |
| Bal, BS | 1 |
| Kant, R | 1 |
| Goff, DC | 1 |
| Gerstein, HC | 1 |
| Ginsberg, HN | 1 |
| Cushman, WC | 1 |
| Margolis, KL | 1 |
| Byington, RP | 1 |
| Buse, JB | 1 |
| Genuth, S | 1 |
| Probstfield, JL | 1 |
| Simons-Morton, DG | 1 |
| Maciejewski, S | 1 |
| Hilleman, D | 1 |
| Vu-Dac, N | 1 |
| Schoonjans, K | 1 |
| Kosykh, V | 1 |
| Dallongeville, J | 1 |
| Staels, B | 2 |
| Auwerx, J | 1 |
| Foxton, J | 1 |
| Banks, D | 1 |
| Lant, AF | 1 |
| Wray, R | 1 |
| Schonfeld, G | 1 |
| Lozada, A | 1 |
| Dujovne, CA | 1 |
| Shepherd, J | 2 |
| Packard, CJ | 3 |
| Schiel, R | 1 |
| Bambauer, R | 1 |
| Müller, UA | 1 |
| Perreault, S | 1 |
| Hamilton, VH | 1 |
| Lavoie, F | 1 |
| Grover, S | 1 |
| Ellen, RL | 1 |
| McPherson, R | 1 |
| Koenig, W | 1 |
| Habib, A | 1 |
| Merval, R | 1 |
| Lebret, M | 1 |
| Torra, IP | 1 |
| Delerive, P | 1 |
| Fadel, A | 1 |
| Chinetti, G | 1 |
| Najib, J | 1 |
| Maclouf, J | 1 |
| Tedgui, A | 1 |
| Paillard, F | 1 |
| Lacan, P | 1 |
| Richard, G | 1 |
| Bontemps, L | 1 |
| Belichard, P | 1 |
| Geyssant, A | 1 |
| Itti, R | 1 |
| Haffner, SM | 2 |
| Li, J | 1 |
| Dai, G | 1 |
| Feng, Z | 1 |
| Wang, C | 1 |
| Wei, W | 1 |
| Zhou, B | 1 |
| Widimský, J | 1 |
| Hulínský, V | 1 |
| Balazovjech, I | 1 |
| Lánská, V | 1 |
| Ashraf, T | 1 |
| Betteridge, DJ | 1 |
| Colhoun, H | 1 |
| Armitage, J | 1 |
| Oldemeyer, JB | 1 |
| Lund, RJ | 1 |
| Koch, M | 1 |
| Meares, AJ | 1 |
| Dunlay, R | 1 |
| Yamashita, T | 1 |
| Nakamura, H | 1 |
| Marx, N | 1 |
| Hombach, V | 1 |
| Vakkilainen, J | 1 |
| Steiner, G | 1 |
| Ansquer, JC | 1 |
| Perttunen-Nio, H | 1 |
| Delaval, D | 1 |
| Simpson, HS | 1 |
| Williamson, CM | 1 |
| Olivecrona, T | 1 |
| Pringle, S | 1 |
| Maclean, J | 1 |
| Lorimer, AR | 1 |
| Bonnefous, F | 1 |
| Bogaievsky, Y | 1 |
| Brown, WV | 1 |
| Leschke, M | 1 |
| Höffken, H | 1 |
| Schmidtsdorff, A | 1 |
| Blanke, H | 1 |
| Egbring, R | 1 |
| Joseph, K | 1 |
| Strauer, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.[NCT01974297] | 194 participants (Anticipated) | Interventional | 2013-07-31 | Recruiting | |||
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
24 reviews available for fenofibrate and Coronary Disease
| Article | Year |
|---|---|
[Impact of dyslipidemia on the onset and progression of diabetic complications].
Topics: Cerebrovascular Disorders; Coronary Disease; Diabetic Angiopathies; Diabetic Nephropathies; Dyslipid | 2013 |
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therap | 2014 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Topics: Anti-HIV Agents; Cholesterol, HDL; Coronary Disease; Dyslipidemias; Fenofibrate; HIV Infections; Hum | 2010 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary | 2002 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Di | 2003 |
Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.
Topics: Body Weight; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Co | 2003 |
Role of fibrates in reducing coronary risk: a UK Consensus.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil | 2004 |
[Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
Topics: Adult; Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2004 |
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Dru | 2005 |
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
Topics: Area Under Curve; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Dr | 2006 |
Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.
Topics: Coronary Disease; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Peroxisome Prolife | 2007 |
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofib | 2007 |
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Topics: Arteriosclerosis; Bezafibrate; Blood Coagulation; Clofibric Acid; Coronary Disease; Fenofibrate; Fib | 1994 |
Drug interactions with fibric acids.
Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Dru | 1994 |
The fibrates in clinical practice: focus on micronised fenofibrate.
Topics: Adolescent; Adult; Aged; Cholesterol, LDL; Coronary Disease; Drug Compounding; Female; Fenofibrate; | 1994 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Overview of fenofibrate.
Topics: Apolipoprotein C-III; Apolipoproteins C; Arteriosclerosis; Coronary Disease; Fenofibrate; Humans; Hy | 1998 |
Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Humans; Hydroxymethylglut | 1998 |
Diabetes, hyperlipidemia, and coronary artery disease.
Topics: Apolipoproteins B; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fenofibrat | 1999 |
[Fenofibrate].
Topics: Animals; Arteriosclerosis; Coronary Disease; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Age | 2001 |
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].
Topics: Animals; Arteriosclerosis; Chromans; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, | 2001 |
Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
Topics: Anticholesteremic Agents; Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as To | 2001 |
Treatment of hypercholesterolaemia with fenofibrate: a review.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Fenofibrate; Humans; Hypercholesterolemia; Propiona | 1989 |
19 trials available for fenofibrate and Coronary Disease
| Article | Year |
|---|---|
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans | 2013 |
Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.
Topics: Aged; Apolipoproteins; Belgium; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind M | 2010 |
Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.
Topics: Aged; Carotid Arteries; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; | 2002 |
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Atorvastatin; Choles | 2003 |
[Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Topics: Adult; Aged; Coronary Disease; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethyl | 2003 |
Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Coronary Disease; Delayed-Action Preparat | 2004 |
Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.
Topics: Analysis of Variance; Coronary Disease; Diet, Mediterranean; Double-Blind Method; Drug Synergism; Fa | 2005 |
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Topics: Aged; Apolipoproteins B; Australia; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Choleste | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Topics: Aged; Cardiovascular Diseases; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blin | 2005 |
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Topics: Adult; Apolipoproteins B; Atorvastatin; Biomarkers; Coronary Disease; Drug Administration Schedule; | 2006 |
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Topics: Antihypertensive Agents; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofib | 2007 |
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Adult; Apolipoprotein A-II; Apolipoproteins E; Base Sequence; Cells | 1995 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, | 1995 |
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Topics: Bezafibrate; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Fenofibrate; Gemf | 1997 |
Lipid-lowering drugs and homocysteine.
Topics: Amino Acids; Coronary Disease; Double-Blind Method; Fenofibrate; Homocysteine; Humans; Hyperlipidemi | 1999 |
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
Topics: Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyspepsia; Exercise Test; F | 1999 |
[Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
Topics: Adult; Aged; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Feno | 1999 |
Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofibrate; H | 2002 |
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
Topics: Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hype | 2002 |
29 other studies available for fenofibrate and Coronary Disease
| Article | Year |
|---|---|
Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; F | 2022 |
Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype.
Topics: Aged; Arachidonic Acids; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Cross-Sectional S | 2013 |
Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
Topics: Aged; Apolipoproteins; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coro | 2014 |
Fenofibric Acid (trilipix).
Topics: Coronary Disease; Drug Approval; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydr | 2009 |
[Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Hu | 2010 |
Combination lipid therapy in type 2 diabetes.
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidem | 2010 |
Trial puts niacin--and cholesterol dogma--in the line of fire.
Topics: Cholesterol, HDL; Coronary Disease; Drug Approval; Fenofibrate; Humans; Hypolipidemic Agents; Niacin | 2011 |
Beyond low-density lipoprotein cholesterol: why, who and when.
Topics: Coronary Disease; Drug Therapy, Combination; Exercise; Fenofibrate; Humans; Hypertriglyceridemia; Hy | 2012 |
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Disease; Fenofibrate; Heptanoic Acids; Humans | 2003 |
Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
Topics: Aged; Chi-Square Distribution; Coronary Disease; Cross-Over Studies; Female; Fenofibrate; Gemfibrozi | 2002 |
[Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].
Topics: Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fenofi | 2002 |
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Topics: Adult; Antioxidants; Apolipoprotein A-I; Apolipoproteins B; Aryldialkylphosphatase; Body Mass Index; | 2003 |
Gout.
Topics: Coronary Disease; Fenofibrate; Gout; Humans; Hypolipidemic Agents; Metabolic Syndrome; Risk Factors; | 2004 |
Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Topics: Aged; Cholesterol, HDL; Coronary Disease; Cost-Benefit Analysis; Female; Fenofibrate; Gemfibrozil; H | 2005 |
Potent capillary isotachophoresis (cITP) for analyzing a marker of coronary heart disease risk and electronegative low-density lipoprotein (LDL) in small dense LDL fraction.
Topics: Biomarkers; Chemical Precipitation; Coronary Disease; Electrophoresis, Capillary; Fenofibrate; Hepar | 2005 |
Correction to the FIELD study report.
Topics: Coronary Disease; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Proportional Hazards M | 2006 |
Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?
Topics: Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; H | 2006 |
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fenofibrat | 2008 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Ki | 1995 |
LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 1996 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cycloox | 1998 |
Effect of low HDL combined with hypertriglyceridemia in coronary artery disease patients on PGI2 biological activity in relation to lipid regulating treatment.
Topics: Coronary Disease; Epoprostenol; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Hyp | 1998 |
Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.
Topics: Coronary Disease; Cost Savings; Cost-Benefit Analysis; Fenofibrate; Glucose Intolerance; Humans; Hyd | 2000 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease | 2000 |
Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Drug Therapy, Combination; Fenofibrate; Gemfibrozil; Hu | 2000 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Postprandial lipemia, fenofibrate and coronary artery disease.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Coronary Disease; Dietary Fats; Diterpenes; | 1990 |
[Effect of fenofibrate on fibrinogen concentration and blood viscosity. Consequences for myocardial microcirculation in coronary heart disease?].
Topics: Blood Viscosity; Coronary Circulation; Coronary Disease; Drug Evaluation; Erythrocyte Aggregation; E | 1989 |
[Regulation of fat metabolism to reduce coronary risk. Product workshop "Clinical results with Normalip 250 N." Copenhagen, 3 June 1989. Abstracts].
Topics: Coronary Disease; Fenofibrate; Humans; Lipid Metabolism; Propionates | 1989 |